Blood and Lymphatic Cancer-Targets and Therapy
Leading citation impact metric from Clarivate Journal Citation Reports
papers with at least that number of citations each
State Council for Professorship (HĐGSNN) Scoring
Quyết định số 26/QĐ-HĐGSNN ngày 11/7/2025 (Mục quốc tế)
HĐGSNN Score History
By article publication year| Year | Max Score | Evaluation Details | Source |
|---|---|---|---|
| 2026 | 1.75đ | WoS Q2 có IF ≥ 2.0(IF: 3.2) | 🔵 Computed |
| 2025 | 1.75đ | WoS Q2 có IF ≥ 2.0(IF: 4.9) | 🔵 Computed |
| 2024 | 1.75đ | WoS Q2 có IF ≥ 2.0(IF: 3.9) | 🔵 Computed |
| 2023 | 1.75đ | WoS Q2 có IF ≥ 2.0(IF: 2.8) | 🔵 Computed |
Note: Domestic journal scores are officially collected from annual HĐGSNN decisions across councils. International journal scores are dynamically computed according to Decision 26/QĐ-HĐGSNN based on quartile and citation metrics in the publication year.
Aims & Scope
Blood and Lymphatic Cancer: Targets and Therapy is an international, peer reviewed, open access journal focusing on blood and lymphatic cancer research, identification of therapeutic targets, and the optimal use of preventative and integrated treatment interventions to achieve improved outcomes, enhanced survival, and quality of life for the cancer patient. Specific topics covered in the journal include: Epidemiology, detection and screening Cellular research and biomarkers Identification of biotargets and agents with novel mechanisms of action Optimal clinical use of existing anticancer agents, including combination therapies Radiation, surgery, bone marrow transplantation Palliative care Patient adherence, quality of life, satisfaction Health economic evaluations.
SCImago & Scopus Journal Intelligence
Not indexed in SCImago / Scopus databaseThis journal is currently not indexed in Scopus or is an academic publication indexed exclusively in Web of Science (WoS).
Chinese Academy of Sciences (CAS) Classification
Major / minor zone classification and CAS Early Warning List history
Publishing & Editorial Information
Detailed publisher, peer-review turnaround, and publication cycle specifications
WoS Categories & Quartiles
Detailed JCR / JCI category rankings and quartile breakdown from Clarivate
| Category | Index | Rank | Quartile |
|---|---|---|---|
ONCOLOGY | JCRESCI | 161/333 | Q2 |
ONCOLOGY | JCIESCI | 181/333 | Q3 |
Annual Historical Statistics & Publications
Track annual publication volume, total citations, and Impact Factor evolution
| Year | Impact Factor | Articles / Year | Total Citations |
|---|---|---|---|
| 2026 | — | 22 | 3 |
| 2025 | 4.9 | 19 | 17 |
| 2024 | 3.9 | 6 | 31 |
| 2023 | 2.8 | 7 | 78 |
| 2022 | — | 12 | 288 |
| 2021 | — | 6 | 105 |
| 2020 | — | 2 | 41 |
| 2019 | — | 8 | 127 |
| 2018 | — | 6 | 202 |
| 2017 | — | 9 | 89 |
| 2016 | — | 5 | 68 |
| 2015 | — | 9 | 30 |
Journal Metrics & Citation Visualizations
Impact Factor Trend (2018–2024)
Clarivate IF trend for Blood and Lymphatic Cancer-Targets and Therapy
Total Cites vs Self-Cites
Evaluation of scholarly independence and citation reach
Citations per Document
Citation metric windows across 2, 3, and 4 years
Similar Journals in Discipline
Journals in the same research field with comparable impact metrics